BusinessTeva Raises 2026 Revenue Forecast as Key Drug Sales ClimbBy Helena WardNov 3, 2026, 2:25 PM UTC
HealthTeva Agrees to U.S. Rights Deal With Up to $420 Million in Upfront and Milestone PaymentsBy Naomi CalderNov 3, 2026, 10:52 AM UTC
HealthTeva to End Midstage MSA Trial After Interim Analysis Signals FutilityBy Naomi CalderNov 2, 2026, 2:03 PM UTC
BusinessAgile Therapeutics Announces Results of its Pre-Submission Meeting with FDABy Nasdaq OMXApr 11, 2017, 11:00 AM UTC
BusinessTEVA REMINDER: Investors With Losses In Excess of $1,000,000 Are Reminded to Contact the Rosen Law Firm Regarding the Important January 5 Deadline in Class Action Filed by Firm- TEVABy Nasdaq OMXDec 27, 2016, 2:00 PM UTC
BusinessRosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Teva Pharmaceutical Industries Limited - TEVABy Nasdaq OMXDec 12, 2016, 11:23 PM UTC
BusinessScott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Securities CaseBy Nasdaq OMXDec 8, 2016, 4:07 PM UTC
BusinessScott+Scott, Attorneys at Law, LLP Reminds Investors of Upcoming Deadline to File Lead Plaintiff Papers in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Securities CaseBy Nasdaq OMXNov 8, 2016, 3:54 PM UTC
